Kidney International®  

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease 

Somatostatin analogues can reduce cyst volume in autosomal dominant polycystic kidney disease (ADPKD), but their effect on kidney function remains uncertain.  

This three-year randomized, placebo-controlled trial tested whether lanreotide could slow kidney function decline in adults with stage 2/3 ADPKD.  

Lanreotide did not slow measured glomerular filtration rate decline, and kidney events and quality of life were similar between groups. Gastrointestinal side effects and hypoglycemia were more common with lanreotide. 

 

Kidney International Reports®  

Predicting high-risk CKD in Japanese people: model development and validation  

Validated risk equations to identify people at high risk of chronic kidney disease (CKD) progression can be challenging to apply in primary care in Japan.  

This study developed and validated a model using routinely available health-check data in Japan to predict progression to high-risk CKD within five years.  

The model performed well and could support earlier risk assessment and management in primary care, although its applicability outside Japan remains uncertain. 

 

Kidney International Case Reports 

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes diagnosed by genetic testing at a freestanding dialysis center: 2 dialysis cases highlighting the diagnostic role of nephrologists 

Mitochondrial diseases can be difficult to recognize in people receiving dialysis because their symptoms overlap with other conditions and may affect multiple organ systems.  

This case report describes two patients with longstanding unexplained symptoms who were diagnosed with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes through genetic testing in a dialysis center.  

The cases highlight how nephrologists’ ongoing contact with dialysis patients can help identify multisystem diseases and prompt further diagnostic evaluation. 

This November, the ISN will contribute to nephrology events in Iran, China, Tunisia, and Sri Lanka, sharing expertise through scientific programs and raising awareness of ISN activities and opportunities. 

 

20th International Congress of Nephrology, Dialysis and Transplantation (ICNDT 2026) 

November 4-6, 2026 Isfahan, Iran 

A recorded talk by ISN President Marcello Tonelli on the WHO resolution on kidney health and its implications will be shown on November 4, from 11:30-12:00, Tehran time. 

 

29th Annual Congress of the Chinese Society of Nephrology (CCSN 2026) 

November 17-21, 2026 Shanghai, China 

The Primer Course in Glomerular Disease, hosted by the ISN and the Chinese Medical Association, will precede the CCSN. 

November 19 

8-8:30 China Time: ISN President Marcello Tonello will deliver a plenary lecture  

14:00 Joint session with ISN speakers 

ISN staff will be on-site; visit them at the ISN booth! 

 

7th Annual Academic Sessions of Sri Lanka Society of Nephrology – NephCon 2026 

November 24-26, 2026 Colombo, Sri Lanka 

The event will feature a recorded talk by ISN President Marcello Tonelli. 

 

Discover all the benefits of ISN-endorsed meetings and how to apply.  

 

Fiona Loud 

A delayed kidney disease diagnosis can affect far more than treatment. It can leave people with little time to understand what is happening, prepare for what comes next, or make informed choices about their care. 

For ISN Patient Liaison Advisory Group member Fiona Loud (UK), the warning signs stretched back years. Kidney damage was first identified after the birth of her daughter, but it was another five years before routine screening for an unrelated problem revealed something was seriously wrong. Fiona was eventually diagnosed with kidney cancer and tuberous sclerosis. She went on to spend five years on dialysis before receiving a kidney transplant from her husband.  

Looking back, Fiona says: “I would very much like to see a system that is better at detecting a condition before it becomes a life-threatening problem. Once identified, I would like to see active treatment and advice; all I was ever given was blood pressure medication and iron.” 

Her experience now informs her extensive advocacy for earlier detection, better access to services, and greater choice for people living with kidney disease. 

Richard Knight 

For Richard Knight (USA), the journey was also marked by delay. While under primary care, his hypertension went unmanaged, and abnormal creatinine results were not treated with the urgency that he later came to understand was required. With unchecked progression of his kidney disease, he needed dialysis with little opportunity to prepare or understand options.  

He also describes the daily, quality-of-life effects that continue long after diagnosis: strict medication schedules, fatigue, infection risk, and the emotional strain of living with uncertainty. “Beyond the physical, there is an invisible emotional tax: the hyperawareness that your health is on borrowed time, managed but never fully resolved. Navigating a healthcare system built around acute care, not chronic management, remains one of the most persistent challenges.” 

Fiona Loud and Richard Knight’s experiences show why listening closely to patients and recognizing the signs earlier are essential to better kidney care and health. While earlier diagnosis cannot remove the challenges of living with kidney disease, it can give people something crucial: time. Time to understand what is happening, consider treatment options, and make decisions about their lives with greater confidence.  

Look out for Rita Charon’s WCN’27 plenary talk: “Narrative Power for Patients and Clinicians: Partners in Health and Care” at WCN’27.    

 

Keep developing your expertise with knowledge and skills you can apply in clinical practice. Your WCN’27 registration includes complimentary access to a range of in-depth courses* that are designed around focused practical learning, case discussions, and expert exchange. 

Register for WCN’27 at the early bird rate 

Explore the full course program 

Onco-Nephrology Course 

Do you manage patients whose kidney and cancer care increasingly overlap? Explore strategies to improve renal and oncological outcomes, including risk assessment, early detection, prevention, and individualized management in complex populations. 

Clinical Trials Course 

Want to get more involved in clinical trials or make them work better in your setting? Follow the journey from starting and running trials to emerging approaches such as AI-supported processes, novel trial designs, and implementation science, with particular attention to resource-limited settings and investigator-led research. 

Conservative Kidney Management Course 

How can you better support patients when kidney replacement therapy is not appropriate, available, or desired? Explore shared decision-making, symptom and metabolic management, terminal care, and practical approaches to delivering goal-directed conservative kidney management across different health care settings. 

Annual Review of Nephrology 

Need a focused update on what is changing in kidney care? Leading experts will review key advances in understanding, diagnosis, and treatment of major conditions, with practical takeaways for clinical practice. 

Renal Pathology Course 

Would greater confidence in kidney biopsy interpretation help with your more complex cases? Get current updates and practical insights into native kidney disease and transplant pathology, with a focus on applying pathology findings to clinical decision-making. 

Allied Health Professionals Course 

How can multidisciplinary teams better support patients throughout the kidney disease journey? Follow case- based discussions from early chronic kidney disease and dialysis through symptom management, conservative kidney care, and quality of life with perspectives from nephrologists, nurses, dietitians, pharmacists, and other allied health professionals. 

This course is also available to allied health professionals without congress registration for USD 100.  

Interventional Nephrology Course 

Looking to build confidence in procedural nephrology? Learn from international experts through lectures, challenging cases, live discussions, and immersive hands-on workshops focused on dialysis access and ultrasound-guided interventions. 

This course requires separate registration and a USD 165 fee. 

Masterclass in Glomerular Diseases 

Looking to deepen your expertise in IgAN and lupus nephritis? This two-day masterclass covers diagnosis, treatment, special populations, and future directions, with opportunities to discuss challenging real-world cases with experts. 

This course requires separate registration and a USD 150 fee. Exclusive for ISN members: Grants are available for complimentary access to the Masterclass. Spots are limited, make sure you apply by November 9.   

Explore the full course program and choose the course that fits your practice 

*Places are limited and available on a first-come, first-served basis on April 1.
 

Combine 2027 ISN membership with WCN’27 registration and save at least USD 115 while enjoying ISN member benefits throughout 2027. 

 

Publishing original research in Kidney International® is already a significant achievement. If you are an eligible early-career researcher, take it further by applying for a KI-ISN Early-Career Researcher Award for the chance to raise the visibility of your work and be recognized at WCN’27.

Apply for a KI-ISN Early-Career Researcher Award by December 11, 2026

Why put your work forward?

At WCN’26, clinical science recipient Ping Liu was recognized for research that highlighted gaps in how kidney failure is identified and recorded, particularly when registries rely solely on kidney replacement therapy. Reflecting on what motivated her to put her work forward, Ping says:

“I applied because I believed our research addressed an important gap in how kidney failure is measured, with implications for research, clinical practice, and health policy.”

Ping Liu, winner of a 2025 KI-ISN Early Career Researcher Award for Clinical Science

Recognition can draw fresh attention to research beyond its original publication and add an internationally recognized distinction to an early-career researcher’s professional profile. For Ping, the benefits extended beyond the award itself:

“The award increased the visibility of my research, particularly within my institution, where the recognition was widely shared. In addition, it provided opportunities to connect with other researchers interested in kidney failure registries and related research, helping to foster new collaborations.”

Could your paper be next?

Four awards are available: two in basic or translational science and two in clinical science, with each recipient receiving USD 500. Applications require a 500-word expression of interest outlining the research and its key findings, alongside a recommendation letter from the applicant’s research mentor.

For early-career researchers considering applying, Ping has straightforward advice:

“I would strongly encourage them to apply. It is a great opportunity to showcase their research to the international kidney community and gain recognition for their work.”

You have already completed the research and published the paper. Take the next step and put your work forward for recognition.

More than 70% of greenhouse gas emissions from kidney care come from the supply chain, making procurement systems a key opportunity to reduce environmental impact. 

A new GREEN-K paper in Kidney International Reports® describes how the ISN-led GREEN-K Working Group developed a proposed global sustainable procurement framework for kidney care.     

Read the paper 

The authors combined an environmental scan with expert interviews and broad consultation across the clinical and industry communities to develop and refine a sustainable procurement framework.  

The paper outlines six areas for more sustainable procurement: decarbonization, supply chain ethics, circularity, health equity, climate resilience, and protection of the living planet. These principles will inform the GREEN-K Joint Statement on Procurement, which will be launched in November. 

Read more about the ISN-led GREEN-K Initiative

Vivekanand Jha named editor-in-chief of Kidney International Reports^®

October 21, 2026

The International Society of Nephrology (ISN) is pleased to announce the appointment of Vivekanand Jha as the next editor-in-chief of Kidney International Reports^® (KIR), an official ISN open-access journal. His term will begin on January 1, 2027, succeeding Jai Radhakrishnan, who has been appointed next editor-in-chief of Kidney International^®.

Jha is a globally recognized nephrologist, researcher, public health leader, and past president of the ISN. He brings extensive experience in kidney disease research, health systems innovation, global kidney care, and scientific publishing.

“Professor Jha is an exceptional choice to lead Kidney International Reports^®,” said ISN President Marcello Tonelli. “His outstanding contributions to global kidney health, commitment to equity and access, and deep understanding of the challenges facing kidney care worldwide align strongly with KIR’s mission.”

“I am honored to take on the role of editor-in-chief of Kidney International Reports^®,” said Professor Jha. “KIR is an important platform for sharing clinical and translational research with the global nephrology community. I look forward to working with the ISN, the editorial team, authors, reviewers, and readers worldwide to build on this strong foundation, support diverse voices in kidney research, and further strengthen the journal’s contribution to improving kidney care.”

Kidney International Reports^® is a peer-reviewed, open-access journal publishing leading research and developments related to kidney health. As part of the ISN Journal family, KIR supports the rapid dissemination of high-quality kidney research and provides an accessible platform for clinical and translational discoveries from the global nephrology community.

Kidney International®  

New insights from DAPA-CKD indicate that dapagliflozin modulates key pathways related to kidney outcomes 

Dapagliflozin improves kidney outcomes in chronic kidney disease (CKD), but the mechanisms behind these benefits are not fully understood.  

This DAPA-CKD proteomic analysis found that dapagliflozin modifies biological pathways linked to CKD progression, particularly those involving inflammation, fibrosis, and tissue remodeling.  

The findings provide new insight into how dapagliflozin may help slow disease progression. 

Kidney International Reports®  

From dialysis expansion to prevention-first kidney care: lessons from Thailand’s response to chronic kidney disease  

Thailand’s experience shows how kidney care can shift from a dialysis-focused model toward prevention, early detection, and integrated care.  

Community screening, multidisciplinary care, sodium-reduction strategies, and wider access to disease-modifying therapies are central to this approach.  

The editorial highlights practical lessons for other low- and middle-income countries seeking to reduce kidney failure while improving equity and sustainability. 

Kidney International Case Reports 

Kidney biopsy findings showing collapsing glomerulopathy with pseudocrescent formation, rather than true crescents, in a patient with an APOL1 G2/G2 genotype 

Misleading pseudocrescents in collapsing glomerulopathy in a patient with APOL1 G2/G2 

This case report describes a young man with acute parvovirus B19 infection and a high-risk APOL1 genotype who developed collapsing glomerulopathy that initially mimicked crescentic glomerulonephritis.  

Definitive pathology identified pseudocrescents rather than true crescents. Despite treatment and clearance of the infection, kidney function continued to decline to kidney failure.  

The case highlights an important diagnostic distinction and the aggressive course of APOL1-associated collapsing glomerulopathy. 

This October, the ISN will contribute to nephrology events in France and Bosnia and Herzegovina. 

11th Annual Congress of Société Francophone de Néphrologie Dialyse et Transplantation (SFNDT) 

October 13-16, 2026 Paris, France 

Join the ISN-ERA Joint Session on Wednesday, October 14, from 14:15-15:30 (Central European Summer Time).  

ISN Emerging Leaders Program member Yannick Nlandu will moderate the session. 

  

21st Balkan Cities Association for Nephrology, Dialysis, Transplantation and Artificial Organs (BANTAO) Congress 2026 

October 29-31, 2026 Sarajevo, Bosnia and Herzegovina 

Thursday, October 29, 9:30-11:00 CET 

Opening plenary session (panel discussion) 

“From Sarajevo to the World: ISN–ERA–BANTAO Dialogue” — Global-Regional Synergy in Kidney Care  

Panelists: Jolanta Malyszko (ISN), Nikolina Bašić-Jukić (ISN), Roser Torra (ERA), Alberto Ortiz (ERA), Halima Resić (BANTAO), Flaviu Bob (BANTAO), Mustafa Arici (BANTAO). 

Moderator: Damir Rebić 

Visit us onsite and find out more about the upcoming WCN’27, and current opportunities and initiatives for ISN members. 

 

Wei Chen presenting at the ISN Frontiers meeting in Dalian, China 

Selected content from the recent ISN Frontiers meeting in Dalian is now available at the ISN Academy.  

Explore ISN Frontiers content 

Discover ISN Frontiers industry content 

Revisit key sessions and industry symposia on emerging treatments, artificial intelligence, rare kidney diseases, cardio-kidney-metabolic care, and more.

Explore the Kidney International Reports^® supplement on ISN Frontiers 2026 abstracts

How should clinicians recognize, assess, and manage acute kidney injury (AKI) linked to infections commonly encountered in tropical settings? 

A new ISN Academy course, “Acute Kidney Injury in the Tropics,” offers a focused review of the pathophysiology, diagnosis, management, and prevention of infection-related AKI, with practical guidance relevant to both adult and pediatric care. 

Explore the course  

Through eight online modules, participants will explore AKI associated with malaria, scrub typhus, dengue, yellow fever, leptospirosis, Ebola virus, HIV, and diarrheal illnesses. Each module includes a 30-minute expert presentation followed by multiple-choice questions to reinforce learning. 

The course will conclude with a live interactive webinar in a roundtable format, allowing participants to discuss real case scenarios with experts and peers. 

Register for the ISN Webinar “Tropical infections and the kidney: presentation, pitfalls, and prevention,” on Wednesday, November 18 at 15:00 CET. 

 

 

Your work has helped move kidney care forward. Could it be time for that contribution to receive international recognition? 

Professional recognition is more than a title. It can signal to colleagues and patients that an igloball professional community has acknowledged your work, experience, and commitment to kidney care. 

The Fellow of the International Society of Nephrology (FISN) designation recognizes established professionals who have demonstrated outstanding accomplishments in research, service, teaching, advocacy, leadership, or other contributions to kidney care. The ISN encourages eligible members from all regions to apply, with particular encouragement to women and colleagues from underrepresented regions. 

Find out more about eligibility and apply for FISN status 

FISN status gives successful applicants the right to use the FISN designation, recognition on the ISN website and at the World Congress of Nephrology, a certificate, and access to the dedicated FISN member community. 

Turn your experience and contribution into a distinction you can carry throughout your career: Apply for FISN status
 

See all FISN awardees  

 

Want to stay at the forefront of global kidney health, deepen your expertise, collaborate with peers worldwide, and access opportunities that can move your career forward? 

In 2027, the ISN is making membership even more accessible to kidney health professionals around the world, while continuing to provide the benefits, resources and opportunities members value. 

Explore the new membership fees 

Join/renew for 2027 at the new, lower fee 

With ISN membership, you can: 

• Keep pace with the latest kidney research through online access to Kidney International® and enjoy reduced publication fees in eligible open-access ISN Journals 

• Build your expertise through 8500+ hours of expert-led learning at the ISN Academy 

• Grow your career and make an impact through fellowships, mentorship, and other ISN Grant initiatives  

• Expand your global network across regions, disciplines, and career stages 

• Help advance kidney health worldwide through ISN committees, working groups, and leadership opportunities in advocacy, research, and education 

Save on your WCN’27 registration with ISN membership 

Combine 2027 ISN membership with WCN’27 registration and save at least USD 115 while enjoying ISN member benefits throughout 2027. 

See how much you can save and register for WCN’27 at the member rate 

You don’t need to wait until January. Once your 2027 membership is confirmed, you can register for WCN’27 at the member rate during 2026. 

Join or renew for 2027 and make the most of everything ISN membership has to offer. 

* The new fees continue to reflect World Bank income classifications. ISN membership remains free for residents in low-income countries and for trainee/student members in their first ISN membership year. 

Behind every diagnosis is a patient with their own experiences, priorities, and story. Narrative medicine asks clinicians to pay closer attention to these stories and how they can inform medical decision-making.  

Rita Charon (USA), a professor of medicine, literary scholar, and co-founder of the field of narrative medicine, will present “Narrative Power for Patients and Clinicians: Partners in Health and Care” at WCN’27.  

Find out more about Professor Charon 

Register for WCN’27 at the early bird rate 

By practicing what Professor Charon calls “radical listening” and incorporating techniques from literary analysis, such as close reading and interpretation, narrative medicine gives practitioners tools to discern better what their patients are communicating.  

This approach is especially relevant in kidney care, where many conditions are long-term, complex, and disruptive to everyday life. By absorbing and analyzing how patients describe these experiences, narrative medicine can strengthen empathy and connection between clinician and patient and support more effective treatment.  

Professor Charon’s session is one of several WCN’27 plenaries bringing perspectives from across and beyond kidney care to explore the clinical, scientific, and human dimensions of caring for people with kidney disease. 

Discover all WCN’27 plenary speakers 

Explore the provisional scientific program

 

This is your opportunity to lead, share your expertise, and collaborate with colleagues from around the world. 

Expressions of interest are now open for positions on ISN committees and working groups for terms starting at the World Congress of Nephrology 2027. 

ISN committee and working group members guide and shape the execution of ISN’s strategic activities and initiatives to advance the ISN’s vision of accessible, sustainable kidney health for all.  

View available vacancies and submit your expression of interest 

Current 2026 ISN members can apply by midnight CET on October 29, 2026. You must renew your membership for 2027 before the appointment begins and keep it active throughout the term. 

Renew your ISN membership for 2027 at the new, lower fee 

World Kidney Day (WKD) launched its 2027 campaign, “Kidneys, heart, and metabolism: the core of your health,” on September 14. The campaign highlights the importance of caring for kidney, cardiovascular, and metabolic health as interconnected parts of overall health.   

Get creative 

This year, WKD invites everyone to take part in the new “Kidney Shape Challenge”: find, create, or capture something kidney-shaped in art, nature, food, or everyday life. Share it on social media, tag World Kidney Day, and use #WorldKidneyDay and #KidneyHealthMatters. The most original idea will receive a special award. 

Apply for a WKD grant 

WKD is also launching a grant program designed to support high-impact initiatives in low- and middle-income countries. Three grants of USD 800 each will help turn local ideas into activities that raise awareness, engage communities, and bring the 2027 campaign to life.  

Find out more and apply by October 30 

Start planning! 

The 2027 activities guide will be released soon with ideas and practical tips. In the meantime, take inspiration from winning activities from previous years, then pin your activity on the WKD map to showcase your plans and inspire others.  

 

Kidney International®  

Real-world outcomes of pegcetacoplan in primary membranoproliferative glomerulonephritis 

Pegcetacoplan is being explored as a treatment for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis, but real-world evidence remains limited.  

This observational study followed 25 pediatric and adult patients treated outside clinical trials, most of whom had not responded to conventional therapies.  

Pegcetacoplan was associated with rapid and sustained reductions in proteinuria, stable or improved kidney function, normalization of serum C3, and good tolerability, supporting its potential as an effective option for complement-mediated kidney disease. 

 

Kidney International Reports®  

Preoperative serum alkaline phosphatase predicts arteriovenous fistula maturation failure   

Arteriovenous fistula (AVF) maturation failure is a major challenge in hemodialysis, but reliable preoperative predictors are limited. 

This study combined multiomics analysis with validation in 55 patients to identify molecular markers linked to AVF maturation failure. 

Higher tissue-nonspecific alkaline phosphatase and preoperative serum alkaline phosphatase were associated with maturation failure, suggesting serum alkaline phosphatase could serve as a practical biomarker to help identify patients at higher risk before AVF creation. 

 

Kidney International Case Reports 

Rescue of renal function after novel RNA interference therapy (lumasiran) for catastrophic post–kidney transplant recurrent oxalate nephropathy in primary hyperoxaluria type 1 

Primary hyperoxaluria type 1 can be difficult to diagnose, and delayed recognition may lead to recurrent oxalate deposition and graft dysfunction after kidney transplantation.  

This case report describes a 23-year-old woman diagnosed only after transplantation, when worsening graft function prompted genetic testing. Lumasiran reduced oxalate levels and stabilized transplant function for 18 months.  

The case highlights the importance of considering genetic or metabolic causes of unexplained kidney failure. It suggests lumasiran may have a role as salvage therapy in selected adults diagnosed after transplantation. 

Start shaping your World Congress of Nephrology 2027 (WCN’27) experience now, with opportunities to get involved before the congress takes place. 

Share your research: Submit an abstract by October 28 

Submit your research to WCN’27 for the chance to share it on a global stage and contribute to the scientific exchange that moves nephrology forward. Previous editions have featured more than 1,500 poster presentations on average. 

Submit your abstract  

Need support to attend? Apply for a travel grant by October 31 

WCN’27 travel grants are available to eligible ISN members living in low- and lower-middle-income countries. Grants include complimentary congress registration and a fixed contribution toward travel and accommodation costs. 

Apply for a travel grant  

Explore focused learning at WCN’27 

Want to go deeper into a particular area of kidney care? From renal pathology to conservative kidney management, all but one of the WCN’27 courses* are complimentary with congress registration and combine expert teaching with practical learning and exchange.  

Explore the WCN’27 courses and find the one that fits your practice 

Start planning now to make WCN’27 work for your research, learning, and professional development. Look out for registration opening soon! 

*The Interventional Nephrology Course requires separate registration and a USD 165 fee. 

 

 

 

​  ​  

Manvir Victor (left) and Bill Wang 

From navigating diagnosis and treatment to the practical and emotional challenges of everyday life, members of the ISN Patient Liaison Advisory Group shared what it means to live with kidney disease.  

Challenging “systemic blindness” in kidney care 

For Bill Wang in Hong Kong, one of the defining challenges was what he describes as “systemic blindness.” Wang has lived with autosomal dominant polycystic kidney disease, dialysis, and a combined liver-kidney transplant. “I had a dual battle,” he explains, “against kidney disease and a system that marginalized lived experience expertise.” 

Bill found that care did not always account for what mattered most to him, including his ability to continue his legal career: “The greatest everyday barrier was a system not designed around what matters most to patients, such as quality of life and life participation.” 

These experiences have led Bill to invest his time in advocating for “moving beyond tokenism” toward genuine co-production and stronger support for lived experience experts, describing this as “the strategic imperative for true patient partnership.” 

Navigating information gaps and employment challenges 

Manvir Victor in Malaysia describes facing kidney disease with little preparation for what treatment and life with the condition would involve. Diagnosed in 2001, he recalls navigating appointments and treatment without understanding what would happen next. 

“Nobody told me anything; I just went to the designated places I was asked to be and waited to be ‘worked on’ by whoever was in charge, with no information.” 

The effects continued beyond treatment. After receiving a transplant, Manvir hoped to return to work but found that his medical history continued to make employment difficult. 

“After multiple job applications, the fact that I was on dialysis for 10 years […] was clearly a barrier to employment,” he explains, adding that doctors are unable to give transplant recipients “a clean bill of health” in a way that reassures prospective employers. “This struggle that many patients go through is often overlooked,” he states. 

In response, Manvir helped establish Malaysian Transplant Heroes, creating opportunities for transplant recipients to showcase their talents and raise awareness of life after kidney disease. 

Despite the challenges he has experienced, Manvir remains hopeful about the future. “The next generation of healthcare professionals is what I am personally optimistic about. They’re growing up in a different world and realize that many things are left to them to change, especially because the evolution of healthcare has been very dynamic and quick, but stunted by outdated processes.”   

Supporting patient perspectives 

Patient voices are central to the ISN’s work to improve kidney health worldwide. 

As part of its involvement in the WHO World Patient Safety Day 2026 Steering Committee, the ISN highlighted PLAG member perspectives on patient safety in a dedicated social media campaign.

Beyond World Patient Safety Day, the ISN will continue to share PLAG members’ stories over the coming months, showing how lived experience can inform care, research, policy, and advocacy and help improve outcomes for people living with kidney disease.

Discover more PLAG members’ stories 

Speakers and delegates at the International Expert Forum: Complement Therapeutics in Clinical Practice in Kidney Disease in Singapore

As complement therapeutics expand across kidney diseases, how should clinicians decide when to use them, how to monitor response, and when to change or stop treatment? 

From September 16-18, 113 experts from 32 countries gathered in Singapore for the ISN International Expert Forum: Complement Therapeutics in Clinical Practice in Kidney Disease to examine these questions and other challenges in using complement-targeting therapies in clinical practice. 

The program covered current evidence for complement therapeutics in aHUS, C3G/IC-MPGN, IgAN, and ANCA-associated vasculitis. It also explored the role of complement in FSGS, diabetic nephropathy, membranous nephropathy, and lupus nephritis. In addition, discussions addressed optimal combination therapies and priorities for future clinical trials.  

The ISN International Expert Forum series brings together leading experts from around the world to examine recent developments, areas of debate, and unmet needs in focused areas of kidney care, helping connect emerging evidence with questions arising in clinical practice. 

The ISN thanks the steering committee, speakers, moderators, and attendees, as well as the event supporters: Alexion, AstraZeneca Rare Disease, Novartis, Biogen, Novo Nordisk, Otsuka, Roche, Sobi, Kira Pharmaceuticals, Bisirna, and Sitala.